SCHEMBL2172968

SCHEMBL2172968

COC(=O)Oc1ccc(N2CCCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.56
ALDH1A1 P00352 9/20 0.56
KMT2A Q03164 6/20 0.56
KDM4E B2RXH2 3/20 0.56
MEN1 O00255 2/20 0.56
GAA P10253 2/20 0.56
RAB9A P51151 2/20 0.55
NR4A1 P22736 1/20 0.55
MCL1 Q07820 1/20 0.55
GFER P55789 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15535616 0.87 CYP1A2 (0.54) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL4812656 0.82 GLA (0.57) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL2172085 0.81 MAPT (0.50) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL676909 0.79 KMT2A (0.58) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL8542788 0.79 ALDH1A1 (0.47) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL2175054 0.78 RAB9A (0.63) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL2176595 0.77 ALDH1A1 (0.76) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL28298689 0.77 GFER (0.56) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL28096400 0.77 ALDH1A1 (0.50) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL5648923 0.76 ALDH1A1 (0.79) MAPTALDH1A1KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 MAPT 2590/4885ALDH1A1 673/4885KMT2A 1912/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 MAPT 3223/4885ALDH1A1 415/4885KMT2A 2227/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 MAPT 2732/4885ALDH1A1 497/4885KMT2A 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.